Protein Biomarker Panel for Shock Mortality Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current risk stratification strategies for patients with cardiogenic shock (CS) and septic shock (SS) are inadequate, leading to high mortality rates and resource utilization, despite the availability of contemporary risk scores like CardShock and IABP-SHOCK II, which rely on basic biochemical tests and lack accuracy.
Innovation Solution
Development of a protein-based classifier using specific proteins (L-FABP, B2MG, ALDOB, and IC1) to predict short-term mortality risk, enhancing discrimination between high and low mortality risk patients through quantitative proteomics analysis and ELISA or mass spectrometry.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If basic biochemical tests and clinical risk scores are used for risk stratification, then the method is simple and routinely available, but the prediction accuracy of mortality risk is insufficient
Solution Approach 1:
The invention changes the parameter being measured from basic biochemical markers to specific protein concentrations (sTNFR1, sTNFR2, sICAM-1, sVCAM-1) that reflect the inflammatory status in cardiogenic shock. This parameter change enables more accurate mortality risk prediction by capturing the systemic inflammatory response that basic tests miss.
Solution Approach 2:
The invention creates a composite risk prediction model that integrates multiple protein markers into a unified inflammatory score. This composite approach combines information from four different proteins to provide a comprehensive assessment of inflammatory status, achieving superior prediction accuracy compared to individual markers or traditional clinical scores alone.
2Measurement precision
If contemporary risk scores like CardShock and IABP-SHOCK II are used, then external validation is available, but they still lack sufficient accuracy for efficient mortality risk prediction
Solution Approach 1:
The invention introduces a new parameter - the inflammatory score based on soluble receptor and adhesion molecule concentrations - that is not captured by existing risk scores. This new parameter provides additional discriminatory power for mortality risk prediction while being measured using routine laboratory techniques.
3Measurement precision
If comprehensive proteomics is performed to discover novel biomarkers, then pathophysiological knowledge and prediction accuracy improve, but the method complexity and cost increase
Solution Approach 1:
The invention extracts and focuses on the most relevant inflammatory markers from the complex proteomic profile, selecting four specific proteins (sTNFR1, sTNFR2, sICAM-1, sVCAM-1) that together provide the predictive information needed. This extraction approach maintains high accuracy while simplifying the test to a manageable panel of markers.
Solution Approach 2:
The selected protein markers serve multiple functions: they reflect inflammatory status, predict mortality risk, and can be measured using routine laboratory methods. This multi-functionality allows the test to provide comprehensive risk assessment without requiring specialized equipment or complex procedures.
Data Source
AI summary
In vitro method for predicting mortality risk in patients suffering from shock. The present invention refers to the medical field. Particularly, it refers to an in vitro method for predicting mortality risk among patients suffering from shock, which comprises determining in a biological sample obtained from the patient the concentration level of specific proteins.